Table 3 Complications and treatment measure of COVID-19 patients
Total (n = 107) | Survivors (n = 88) | Non-survivors (n = 19) | |
|---|---|---|---|
Complications | |||
Shock | 22 (20.6) | 3 (3.4) | 19 (100.0) |
Acute cardiac injury | 12 (11.2) | 4 (4.5) | 8 (42.1) |
ARDS | 28 (26.2) | 11 (12.5) | 17 (89.5) |
Acute kidney injury | 14 (13.1) | 0 (0.0) | 14 (73.7) |
Evidence of co-infection | |||
Bacterial | 5 (4.7) | 1 (1.1) | 4 (21.1) |
Viral | 12 (11.2) | 10 (11.4) | 2 (10.5) |
Treatment | |||
Antiviral therapy | 105 (98.1) | 87 (98.9) | 18 (94.7) |
Oseltamivir | 95 (88.8) | 77 (87.5) | 18 (94.7) |
Arbidol | 33 (30.8) | 33 (37.5) | 0 (0.0) |
Antibiotic therapy | 85 (79.4%) | 67 (76.1) | 18 (94.7) |
Glucocorticoid therapy | 62 (57.9) | 44 (50.0) | 18 (94.7) |
CRRT | |||
Oxygen therapy | 4 (3.7) | 0 (0.0) | 4 (21.1) |
Oxygen inhalation | 80 (74.8) | 78 (88.6) | 2 (10.5) |
Non-invasive ventilation | 7 (6.5) | 7 (8.0) | 0 (0.0) |
IMV alone | 17 (15.9) | 1 (1.1) | 16 (84.2) |
IMV plus ECMO | 3 (2.8) | 2 (2.3) | 1 (5.3) |